FDA Drug Shortage Database
Carboplatin (Kyxata) shortage
The FDA Drug Shortage Database lists 25 of 35 carboplatin presentations as limited or unavailable (updated October 6, 2026); the first entry was posted on April 28, 2023. 4 more presentations are on the list as available.
- Generic listed
- In shortage
- Boxed warning
Check it at the source: the FDA Drug Shortage Database.
Which strengths are short?
| Strength | Limited or unavailable now | Listed now, available | Resolved or discontinued |
|---|---|---|---|
| 10mg/1ml injection | 9 | 0 | 0 |
| 50mg/5ml injection | 4 | 0 | 1 |
| 80mg/8ml injection | 0 | 1 | 0 |
| 150mg/15ml injection | 3 | 1 | 1 |
| 450mg/45ml injection | 5 | 0 | 2 |
| 500mg/50ml injection | 0 | 1 | 0 |
| 600mg/60ml injection | 3 | 1 | 2 |
| 600mg/65ml injection | 1 | 0 | 0 |
Which presentations are listed?
Limited or unavailable now (25)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01) | Teva Pharmaceuticals USA, Inc. | Current posted April 28, 2023, updated October 1, 2026 | Limited Availability; Other |
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01) | Teva Pharmaceuticals USA, Inc. | Current posted April 28, 2023, updated October 1, 2026 | Unavailable; Other |
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01) | Teva Pharmaceuticals USA, Inc. | Current posted April 28, 2023, updated October 1, 2026 | Limited Availability; Other |
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01) | Teva Pharmaceuticals USA, Inc. | Current posted April 28, 2023, updated October 1, 2026 | Limited Availability; Other |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12) | Accord Healthcare Inc. | Current posted April 28, 2023, updated October 3, 2026 | Unavailable; Requirements related to complying with good manufacturing practices |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31) | Accord Healthcare Inc. | Current posted April 28, 2023, updated October 3, 2026 | Unavailable; Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33) | Accord Healthcare Inc. | Current posted April 28, 2023, updated October 3, 2026 | Unavailable; Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34) | Accord Healthcare Inc. | Current posted April 28, 2023, updated October 3, 2026 | Unavailable; Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60) | Fresenius Kabi USA, LLC | Current posted April 28, 2023, updated October 6, 2026 | Unavailable; Delay in shipping of the drug |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05) | Hospira, Inc., a Pfizer Company | Current posted April 28, 2023, updated September 22, 2026 | Unavailable; Other |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22) | Hospira, Inc., a Pfizer Company | Current posted April 28, 2023, updated September 22, 2026 | Limited Availability; Other |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3) | Teyro Labs | Current posted April 28, 2023, updated October 1, 2026 | Unavailable; Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05) | Hospira, Inc., a Pfizer Company | Current posted April 28, 2023, updated September 22, 2026 | Unavailable; Other |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50) | Hospira, Inc., a Pfizer Company | Current posted April 28, 2023, updated September 22, 2026 | Limited Availability; Demand increase for the drug |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6) | Teyro Labs | Current posted April 28, 2023, updated October 1, 2026 | Unavailable; Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01) | Eugia US LLC | Current posted April 28, 2023, updated October 2, 2026 | Unavailable; Demand increase for the drug |
| Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01) | Gland Pharma Limited | Current posted April 28, 2023, updated September 15, 2026 | Limited Availability; Demand increase for the drug |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18) | Hospira, Inc., a Pfizer Company | Current posted April 28, 2023, updated September 22, 2026 | Limited Availability; Demand increase for the drug |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18) | Hospira, Inc., a Pfizer Company | Current posted April 28, 2023, updated September 22, 2026 | Unavailable; Other |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1) | Teyro Labs | Current posted April 28, 2023, updated October 1, 2026 | Unavailable; Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01) | Gland Pharma Limited | Current posted April 28, 2023, updated September 15, 2026 | Unavailable; Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56) | Hospira, Inc., a Pfizer Company | Current posted April 28, 2023, updated September 22, 2026 | Limited Availability; Other |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05) | Hospira, Inc., a Pfizer Company | Current posted April 28, 2023, updated September 22, 2026 | Unavailable; Other |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7) | Teyro Labs | Current posted April 28, 2023, updated October 1, 2026 | Unavailable; Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01) | Gland Pharma Limited | Current posted April 28, 2023, updated September 15, 2026 | Limited Availability; Demand increase for the drug |
Listed now, available (4)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01) | Gland Pharma Limited | Current posted April 28, 2023, updated September 15, 2026 | Available |
| Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01) | Eugia US LLC | Current posted April 28, 2023, updated October 2, 2026 | Available |
| Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50) | Avyxa Pharma, LLC | Current posted April 28, 2023, updated September 1, 2026 | Available |
| Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08) | Avyxa Pharma, LLC | Current posted April 28, 2023, updated September 1, 2026 | Available |
Resolved or discontinued (6)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3) | Teyro Labs | To Be Discontinued posted June 1, 2026, updated June 1, 2026 | not given |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6) | Teyro Labs | To Be Discontinued posted June 1, 2026, updated June 1, 2026 | not given |
| Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45) | Ingenus Pharmaceuticals LLC | To Be Discontinued posted February 20, 2026, updated February 20, 2026 | not given |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1) | Teyro Labs | To Be Discontinued posted June 1, 2026, updated June 1, 2026 | not given |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7) | Teyro Labs | To Be Discontinued posted June 1, 2026, updated June 1, 2026 | not given |
| Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60) | Ingenus Pharmaceuticals LLC | To Be Discontinued posted February 20, 2026, updated February 20, 2026 | not given |
Source: FDA Drug Shortage Database via openFDA, read October 8, 2026
What next?
- Every shortage now
- medicines by presentations in shortage